Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

JenaValve appoints medtech veteran Drachman CEO

This article was originally published in Clinica

Executive Summary

German transcatheter aortic valve developer JenaValve has made David Drachman CEO, replacing Helmut Straubinger, who has headed up the company since 2006. Mr Drachman, who JenaValve hopes will help position it as “a significant player in the TAVI space,” has 30 years of experience in the cardiovascular medical device industry. Most recently, he was president and CEO of atrial fibrillation treatment specialist AtriCure from 2002 until September 2012. Before this, he was at Biosense Webster, which has since become part of Johnson & Johnson; and previously led Impulse Dynamics. Mr Drachman has also worked for Ventritex and Boston Scientific.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT101719

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel